Related Experiment Video
Updated: Oct 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Interferon for adjuvant therapy in melanoma; although approved, not indicated]
G Groenewegen1, S Osanto, H J van der Rhee
1Afd. Interne Geneeskunde, Universitair Medisch Centrum Utrecht. g.groenewegen@azu.nl
Abstract:
The Dutch melanoma group reconsidered their 1997 consensus statement on treatment of melanoma because new studies on adjuvant treatment with interferon(IFN)-alpha have been published. These have resulted in its registration for stage IIa; for stage IIb/III IFN-alpha was already registered. Overall survival should be the main endpoint of adjuvant clinical studies, especially when treatment is associated with toxicity. Since a benefit has not been unequivocally demonstrated in melanoma with Breslow thickness > 1.5 mm and/or regional lymph node metastases, there is no need to change the Dutch consensus statement. Drug registration authorities and medical professionals should cooperate more closely.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

